Drug Approval | October 16, 2024
Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic NSCLC
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Sales reflect continued strong growth in oncology and vaccines
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Subscribe To Our Newsletter & Stay Updated
